HNGE Company Profile and Key Details

Hinge Health, Inc. has 27.22 million shares outstanding. The public float is 21.69 million shares, elevated short interest at 4.32% of float. This equals 1.12 million shares. The short ratio is 1.4 days. Institutional investors hold 115.84% of the float. Insiders own 5.81%. Bessemer Venture Partners X L.P. holds 3.38 million shares, Pursley James has 740.90 thousand shares and Budge James has 445.39 thousand shares. Over the past six months, insider transactions show net selling. They sold 549.82 thousand shares across 32 transactions.

HNGE has shown weak momentum, losing -14.13% over the past week and -15.54% over the past quarter, though year-to-date performance is down -10.4%. Short-term trend indicators are bullishly aligned (SMA20 17.41%, SMA50 3.1%, SMA200 -7.11%). The stock’s 14-day RSI is 60.61 (firm momentum), while the ATR of 2.48 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -29.77% below its high and over 45.18% above its low. Average 10-day trading volume of 1.54 million shares is below the 3-month average of 2.00 million, indicating normal recent market interest.

Our AI price prediction model suggests that Hinge Health, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -14.43%, with price expected at $64.39 by August 11, 2026, within a range of $60.26 to $68.30 3-Month Outlook: Projected rise of 3.71%, reaching $78.04 by October 23, 2026, with a range of $77.07 to $78.95. 1-Year Outlook: Projected gain of 15.75%, with price at $87.10 by July 28, 2027, within a range of $83.71 to $90.30.

Hinge Health, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $27.31. This means the shares are trading above this model’s fair value.

Hinge Health, Inc. (NYSE:HNGE) shares are down -10.4% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Hinge Health, Inc. trading at a premium to the broader market with a P/E of -11.41. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $65.83, suggesting -12.52% downside. Our AI forecast model points to short-term weakness (-14.43% over two weeks), a medium-term rise (3.71% over three months), and a longer-term gain (15.75% over one year), with expected trading ranges indicating moderate volatility.

Hinge Health, Inc. (NYSE:HNGE) closed at $75.25 USD, gaining $0.14 (0.19%) from the previous close of $75.11. The stock is currently mid-range between its 52-week high and low $30.08 and $91.50. With a market capitalization of about $5.82 billion, Hinge Health, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.11). Key stats such as the average daily volume over the past year has been around 1.99 million shares, volume is running light vs its 52-week average. Headquartered in San Francisco, CA, Hinge Health, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Daniel A. Perez, the company employs approximately 1,437 people and listed since May 22, 2025. Established in 2012 and headquartered in San Francisco, California, Hinge Health, Inc. creates specialized healthcare software solutions for musculoskeletal and joint health.

Wall Street analysts project EPS growth of 1.95% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 31 Strong Buy ratings, 19 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $125.00 to $45.00. The high target offers 66.11% upside. The low target suggests -40.2% downside. The mean target is $70.65. This offers -6.11% upside. Hinge Health, Inc. earnings surprise history is a mixed track record. The quarter that ended May 05, 2026, missed forecasts by 15.38%. The prior quarter beat by 1125.0%. Over the last six quarters, Apple has recorded several small beats. These include 644.44% in August 05, 2025.

Hinge Health, Inc. trades at a P/E ratio of -11.41, slightly below the S&P 500 average, with a price-to-sales ratio of 8.99 and a price-to-book ratio of 18.96 reflecting a rich premium to book value. The P/FCF stands at 28.19, also above market averages. Compared to sector medians, Hinge Health, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.